TrialTargeted oncology2016

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.

Aaron Vinik et al.PubMed ↗Publisher ↗

No numbers read from the abstract.